Elevated CCL20 expression associates with adverse prognosis in breast cancer patients: A clinical perspective.

Xia Zhao, Yanping Li, Yu Feng, Shuzhen Lv
{"title":"Elevated CCL20 expression associates with adverse prognosis in breast cancer patients: A clinical perspective.","authors":"Xia Zhao, Yanping Li, Yu Feng, Shuzhen Lv","doi":"10.1097/JCMA.0000000000001233","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The chemokine CCL20 exhibits pronounced expression within tumor cells, effectively facilitating tumor progression by modulating the immunosuppressive microenvironment and promoting tumor cell aggressiveness.</p><p><strong>Methods: </strong>Breast cancer and matched adjacent normal tissues from 113 adult breast cancer patients were collected for immunohistochemical staining of CCL20, E-Cadherin, Vimentin, and N-Cadherin. The assessment evaluated the association between CCL20 expression and clinicopathological factors using Pearson's chi-squared test, EMT markers expression using Spearman's rank correlation test, both OS and DFS using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling.</p><p><strong>Results: </strong>Cytoplasmic CCL20 expression was stronger in cancer tissues, compared to normal tissue (69.9% vs 23%). Strong correlations were observed between CCL20 expression and many clinicopathological features, including tumor size (p = 0.000), estrogen receptor (ER) status (p = 0.003), Ki67 status (p = 0.000), vascular invasion (p = 0.001), and tumor-node-metastasis stage (p = 0.001). Additionally, CCL20 expression was an independent prognostic predictor for OS (HR, 3.207; 95% confidence interval [CI], 1.142 - 9.005, p = 0.027). Furthermore, a significant association between CCL20 expression and EMT markers was observed. CCL20 expression was linked to unfavorable outcomes in all patients (p = 0.000), ER-positive patients (p = 0.001), and node-positive/negative (p = 0.005/0.001) subgroups.</p><p><strong>Conclusion: </strong>These findings highlighted that elevated CCL20 expression was linked to a more aggressive tumor phenotype and a disappointing OS in breast cancer patients, thus advocating for the consideration of CCL20 expression being a novel independent prognostic biomarker for guiding bespoke treatment strategies.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Chinese Medical Association : JCMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JCMA.0000000000001233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The chemokine CCL20 exhibits pronounced expression within tumor cells, effectively facilitating tumor progression by modulating the immunosuppressive microenvironment and promoting tumor cell aggressiveness.

Methods: Breast cancer and matched adjacent normal tissues from 113 adult breast cancer patients were collected for immunohistochemical staining of CCL20, E-Cadherin, Vimentin, and N-Cadherin. The assessment evaluated the association between CCL20 expression and clinicopathological factors using Pearson's chi-squared test, EMT markers expression using Spearman's rank correlation test, both OS and DFS using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling.

Results: Cytoplasmic CCL20 expression was stronger in cancer tissues, compared to normal tissue (69.9% vs 23%). Strong correlations were observed between CCL20 expression and many clinicopathological features, including tumor size (p = 0.000), estrogen receptor (ER) status (p = 0.003), Ki67 status (p = 0.000), vascular invasion (p = 0.001), and tumor-node-metastasis stage (p = 0.001). Additionally, CCL20 expression was an independent prognostic predictor for OS (HR, 3.207; 95% confidence interval [CI], 1.142 - 9.005, p = 0.027). Furthermore, a significant association between CCL20 expression and EMT markers was observed. CCL20 expression was linked to unfavorable outcomes in all patients (p = 0.000), ER-positive patients (p = 0.001), and node-positive/negative (p = 0.005/0.001) subgroups.

Conclusion: These findings highlighted that elevated CCL20 expression was linked to a more aggressive tumor phenotype and a disappointing OS in breast cancer patients, thus advocating for the consideration of CCL20 expression being a novel independent prognostic biomarker for guiding bespoke treatment strategies.

乳腺癌患者CCL20表达升高与不良预后相关:临床观点
背景:趋化因子CCL20在肿瘤细胞中表达明显,通过调节免疫抑制微环境,促进肿瘤细胞侵袭性,有效促进肿瘤进展。方法:收集113例成年乳腺癌患者的乳腺癌及匹配的癌旁正常组织,进行CCL20、E-Cadherin、Vimentin、N-Cadherin的免疫组化染色。采用Pearson卡方检验评估CCL20表达与临床病理因素的关系,采用Spearman秩相关检验评估EMT标志物表达,采用Kaplan-Meier生存分析和Cox比例风险回归模型评估OS和DFS。结果:细胞质CCL20在癌组织中的表达强于正常组织(69.9%比23%)。CCL20表达与肿瘤大小(p = 0.000)、雌激素受体(ER)状态(p = 0.003)、Ki67状态(p = 0.000)、血管浸润(p = 0.001)和肿瘤淋巴结转移分期(p = 0.001)等多种临床病理特征密切相关。此外,CCL20表达是OS的独立预后预测因子(HR, 3.207;95%可信区间[CI], 1.142 ~ 9.005, p = 0.027)。此外,CCL20表达与EMT标志物之间存在显著关联。在所有患者(p = 0.000)、er阳性患者(p = 0.001)和淋巴结阳性/阴性(p = 0.005/0.001)亚组中,CCL20表达与不良结局相关。结论:这些发现强调了CCL20表达升高与乳腺癌患者更具侵袭性的肿瘤表型和令人失望的OS相关,因此提倡将CCL20表达作为一种新的独立预后生物标志物来指导定制治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信